[ad_1]
By Davit Kirakosyan
10x Genomics, Inc. (NASDAQ:) shares dropped more than 12% after-hours following the company’s preliminary Q2 results, with revenue expected to be approximately $114.5 million (down 1% year-over-year), missing the Street estimate of $127.7 million.
“Our second quarter results fell short of our expectations,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “We continue to have strong confidence in our longer-term opportunity, technology leadership and the underlying strength of our markets. We are more excited than ever to deliver on the full potential of single cell and spatial biology.”
Forex prop trading firms have become an increasingly popular part of the financial industry. These…
In the present fast-paced world, homeowners are generally constantly seeking innovative approaches to enhance the…
Malta's sparkling blue waters beckon yacht charterers to discover one of the Mediterranean's tiniest countries.…
Real estate website development can be an effective way of reaching new customers and increasing…
Betting on games can be thrilling and profitable if you are an avid football fan,…
Introduction: Tennis, with its blend of finesse, power, and strategy, captivates both players and spectators…